Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gyo Asai

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 17, 2020
[Superior Vena Cava Syndrome]Chiaki Kondo, Gyo Asai
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancerGyo Asai, Nobuyuki Yamamoto, Takayasu Kurata, et al.
Case Reports in Medicine|April 16, 2015
Balloon Dilatation of a Case of Tuberculous Tracheobronchial Stenoses during the Course of Antituberculous TreatmentShimaa Nour Moursi Ahmed, Potjanee Korrungruang, Hideo Saka, et al.
Cancer Science|January 20, 2007
Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancerToru Itaya, Nobuyuki Yamaoto, Masahiko Ando, et al.
Anticancer Research|June 3, 2006
Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancerNobuyuki Yamamoto, Junji Tsurutani, Naruo Yoshimura, et al.
Cancer Chemotherapy and Pharmacology|July 11, 2002
Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancerGyo Asai, Nobuyuki Yamamoto, Masakazu Toi, et al.
The Lancet. Oncology|April 13, 2019
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, et al.
The Lancet. Respiratory Medicine|August 29, 2021
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trialYosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, et al.
Ebiomedicine|July 7, 2020
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 studyTatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 17, 2020
[Superior Vena Cava Syndrome]Chiaki Kondo, Gyo Asai
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancerGyo Asai, Nobuyuki Yamamoto, Takayasu Kurata, et al.
Case Reports in Medicine|April 16, 2015
Balloon Dilatation of a Case of Tuberculous Tracheobronchial Stenoses during the Course of Antituberculous TreatmentShimaa Nour Moursi Ahmed, Potjanee Korrungruang, Hideo Saka, et al.
Cancer Science|January 20, 2007
Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancerToru Itaya, Nobuyuki Yamaoto, Masahiko Ando, et al.
Anticancer Research|June 3, 2006
Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancerNobuyuki Yamamoto, Junji Tsurutani, Naruo Yoshimura, et al.
Cancer Chemotherapy and Pharmacology|July 11, 2002
Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancerGyo Asai, Nobuyuki Yamamoto, Masakazu Toi, et al.
The Lancet. Oncology|April 13, 2019
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, et al.
The Lancet. Respiratory Medicine|August 29, 2021
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trialYosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, et al.
Ebiomedicine|July 7, 2020
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 studyTatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, et al.
Pageof 1